BPR3P0128
BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC50 for SARS-CoV-2 and HCoV-229E are 0.62 μM and 0.14 μM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir.
Product Specifications
CAS Number
1345406-09-8
UNSPSC
12352005
Target
SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/bpr3p0128.html
Purity
98.58
Solubility
10 mM in DMSO
Smiles
O=C(O)C1=CC(C2=C(C)N(C3=CC(C)=CC=C3C)N=C2)=NC4=CC=C(Br)C=C41
Molecular Formula
C22H18BrN3O2
Molecular Weight
436.30
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
UBXD5 (UBXN11) (NM_001077262) Human Over-expression Lysate
C3orf23 (TCAIM) (NM_173826) Human Recombinant Protein
Maltose Binding Protein / MBP-probe (R29.6), CF488A conjugate, 0.1mg/mL
![STAT3 Recombinant Rabbit Monoclonal Antibody [SY34-01]](https://cdn.genprice.uk/products/992/68dd1c8a061270361ea81394/imageurl/et1605-45.webp)